SCHEMBL5440367

SCHEMBL5440367

COC(=O)c1ccc(I)c(NS(C)(=O)=O)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.70
SMN1; SMN2 Q16637 2/20 0.70
HSD17B10 Q99714 2/20 0.70
POLB P06746 1/20 0.55
ALDH1A1 P00352 8/20 0.51
HPGD P15428 4/20 0.51
MAPT P10636 1/20 0.51
HTT P42858 1/20 0.49
CYP2C9 P11712 5/20 0.48
TSHR P16473 3/20 0.47
MAPK10 P53779 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA7 P43166 1/20 0.45
XDH P47989 1/20 0.45
CA9 Q16790 1/20 0.45
CA14 Q9ULX7 1/20 0.45
MEN1 O00255 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5450879 0.88 KDM4E (0.66) KDM4ESMN1; SMN2HSD17B10POLBALDH1A1
SCHEMBL3237044 0.85 KDM4E (0.77) KDM4ESMN1; SMN2HSD17B10POLBALDH1A1
SCHEMBL7116517 0.84 SMN1; SMN2 (0.53) KDM4ESMN1; SMN2HSD17B10ALDH1A1HPGD
SCHEMBL8068415 0.83 KDM4E (0.72) KDM4ESMN1; SMN2HSD17B10POLBALDH1A1
SCHEMBL4175701 0.83 KDM4E (0.72) KDM4ESMN1; SMN2HSD17B10POLBALDH1A1
SCHEMBL5071184 0.81 SMN1; SMN2 (0.70) KDM4ESMN1; SMN2HSD17B10POLBALDH1A1
SCHEMBL14389382 0.81 KDM4E (0.70) KDM4ESMN1; SMN2HSD17B10POLBALDH1A1
SCHEMBL4952535 0.81 KDM4E (0.70) KDM4ESMN1; SMN2HSD17B10POLBALDH1A1
SCHEMBL15754401 0.81 KDM4E (0.70) KDM4ESMN1; SMN2HSD17B10POLBALDH1A1
SCHEMBL22391857 0.80 CYP2C9 (0.76) KDM4ESMN1; SMN2HSD17B10POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070135485-A1 Novel mch receptor antagonists ELI LILLY AND COMPANY 2007-06-14 US disclosed
US-20070135485-A1 Novel mch receptor antagonists ELI LILLY AND COMPANY 2007-06-14 US disclosed
US-20070135485-A1 Novel mch receptor antagonists ELI LILLY AND COMPANY 2007-06-14 US disclosed
EP-1723126-A2 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2006-11-22 EP disclosed
WO-2005040157-A2 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135485-A1 Novel mch receptor antagonists MCHR1, MCHR2, MC1R KDM4E 1471/4885SMN1; SMN2 2528/4885HSD17B10 780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.